Identification

Name
Desloratadine
Accession Number
DB00967  (APRD00324)
Type
Small Molecule
Groups
Approved, Investigational
Description

Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.

Structure
Thumb
Synonyms
  • 8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
  • 8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
  • Descarboethoxyloratadine
  • DESLORATADINE
External IDs
SCH 34117 / SCH-34117
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ClarinexTablet, film coated5 mg/1OralPhysicians Total Care, Inc.2002-06-03Not applicableUs
ClarinexTablet, film coated5 mg/1OralA S Medication Solutions2001-12-212017-06-20Us
ClarinexTablet, film coated5 mg/1OralRebel Distributors2002-02-08Not applicableUs
ClarinexTablet, film coated5 mg/1OralMerck Sharp & Dohme Limited2001-12-21Not applicableUs00085 1264 01 nlmimage10 cc07e63f
ClarinexSolution.5 mg/mLOralMerck Sharp & Dohme Limited2004-09-01Not applicableUs
NeoclaritynTablet, orally disintegrating2.5 mgOralMerck Sharp & Dohme B.V.2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme B.V.2001-01-15Not applicableEu
NeoclaritynSolution0.5 mg/mlOralMerck Sharp & Dohme B.V.2001-01-15Not applicableEu
NeoclaritynTablet, orally disintegrating5 mgOralMerck Sharp & Dohme B.V.2001-01-15Not applicableEu
NeoclaritynTablet, film coated5 mgOralMerck Sharp & Dohme B.V.2001-01-15Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DasseltaTablet, film coated5 mgOralKrka, D.D., Novo Mesto2011-11-28Not applicableEu
DesloratadineTablet, film coated5 mg/1OralPaddock Laboratories, Inc.2014-01-102017-10-26Us
DesloratadineTablet, film coated5 mg/1OralSun Pharmaceutical Industries Limited2010-11-24Not applicableUs62756 0523 88 nlmimage10 2a3a1510
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AeriusSyrup0.5 mgOralBayerNot applicableNot applicableCanada
AeriusTablet5 mgOralBayer2002-01-10Not applicableCanada
Aerius KidsSyrup0.5 mgOralBayer2005-03-21Not applicableCanada
Allergy Control DesloratadineTablet5 mgOralPharmascience IncNot applicableNot applicableCanada
Allernix Multi SymptomTablet5 mgOralTeva2012-01-31Not applicableCanada
Desloratadine Allergy ControlTablet5 mgOralDominion Pharmacal2014-03-10Not applicableCanada
Desloratadine Allergy ControlTablet5 mgOralPharmascience Inc2009-12-24Not applicableCanada
Desloratadine TabletsTablet5 mgOralApotex Corporation2010-05-27Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aerius Dual Action 12 HourDesloratadine (2.5 mg) + Pseudoephedrine sulfate (120 mg)Tablet, extended releaseOralBayer2010-02-01Not applicableCanada
Aerius Dual Action 24 HourDesloratadine (5 mg) + Pseudoephedrine sulfate (240 mg)Tablet, multilayer, extended releaseOralBayerNot applicableNot applicableCanada
Clarinex-D 12 HourDesloratadine (2.5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, extended releaseOralPhysicians Total Care, Inc.2006-11-29Not applicableUs
Clarinex-D 12 HourDesloratadine (2.5 mg/1) + Pseudoephedrine sulfate (120 mg/1)Tablet, extended releaseOralMerck Sharp & Dohme Limited2006-02-01Not applicableUs00085 1322 01 nlmimage10 cf07e78f
International/Other Brands
Claramax / NeoClarityn
Categories
UNII
FVF865388R
CAS number
100643-71-8
Weight
Average: 310.821
Monoisotopic: 310.123676325
Chemical Formula
C19H19ClN2
InChI Key
JAUOIFJMECXRGI-UHFFFAOYSA-N
InChI
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
IUPAC Name
13-chloro-2-(piperidin-4-ylidene)-4-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3(8),4,6,12,14-hexaene
SMILES
ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1

Pharmacology

Indication

For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.

Associated Conditions
Pharmacodynamics

Desloratadine is a long-acting second-generation H1-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.

Mechanism of action

Like other H1-blockers, Desloratadine competes with free histamine for binding at H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

82-87%

Metabolism
Not Available
Route of elimination

Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. Approximately 87% of a 14C-desloratadine dose was equally recovered in urine and feces.

Half life

50 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Desloratadine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Desloratadine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Desloratadine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Desloratadine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Desloratadine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Desloratadine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Aceprometazine.Approved
AclidiniumDesloratadine may increase the anticholinergic activities of Aclidinium.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Desloratadine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alfentanil.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desloratadine.Approved, Illicit, Investigational
AmbenoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Ambenonium.Approved
AmisulprideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desloratadine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Desloratadine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Desloratadine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Desloratadine.Approved, Illicit, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Desloratadine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desloratadine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Desloratadine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Desloratadine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Desloratadine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Azaperone.Investigational, Vet Approved
AzelastineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Desloratadine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Desloratadine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Desloratadine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Desloratadine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benzocaine.Approved, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Desloratadine.Approved, Illicit
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Desloratadine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineDesloratadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Desloratadine.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Desloratadine.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Desloratadine.Experimental
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Desloratadine.Approved
Botulinum Toxin Type ADesloratadine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDesloratadine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved, Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Desloratadine.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Desloratadine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Desloratadine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Desloratadine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desloratadine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Bupivacaine.Approved, Investigational
BuprenorphineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Desloratadine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desloratadine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Desloratadine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Desloratadine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Desloratadine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Desloratadine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desloratadine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Desloratadine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desloratadine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Desloratadine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desloratadine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chloroprocaine.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Desloratadine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorphenoxamine.Withdrawn
ChlorphentermineChlorphentermine may decrease the sedative activities of Desloratadine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desloratadine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Desloratadine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desloratadine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Desloratadine.Approved, Investigational
CimetropiumDesloratadine may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Desloratadine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Desloratadine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Desloratadine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Desloratadine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Desloratadine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Desloratadine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desloratadine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Desloratadine.Approved
CocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Desloratadine.Approved
CoumaphosThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Coumaphos.Vet Approved
CyclizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desloratadine.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Desloratadine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Desloratadine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Desloratadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desloratadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Desloratadine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Demecarium.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Desloratadine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desloratadine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Desloratadine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Desloratadine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desloratadine.Approved, Illicit, Investigational, Vet Approved
DichlorvosThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Desloratadine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Desloratadine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Desloratadine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desloratadine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Dipivefrin.Approved
DistigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Distigmine.Experimental
DixyrazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dixyrazine.Experimental
DonepezilThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Desloratadine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Desloratadine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ecgonine.Experimental, Illicit
EchothiophateThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Echothiophate.Approved
EcopipamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Desloratadine.Approved
EdrophoniumThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desloratadine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Eltanolone.Investigational
EluxadolineDesloratadine may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Emepronium.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Desloratadine.Approved, Investigational
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Desloratadine.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Desloratadine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Desloratadine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desloratadine.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etanautine.Experimental
EthanolDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Desloratadine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Desloratadine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Desloratadine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Etybenzatropine.Experimental
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Desloratadine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Desloratadine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Desloratadine.Approved, Investigational
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Desloratadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Desloratadine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desloratadine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desloratadine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Desloratadine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desloratadine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Gabapentin Enacarbil.Approved, Investigational
GalantamineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Desloratadine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Desloratadine.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Desloratadine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Desloratadine is combined with Gepirone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Desloratadine is combined with Glucagon recombinant.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumDesloratadine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desloratadine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Homatropine.Approved
Human secretinThe therapeutic efficacy of Human secretin can be decreased when used in combination with Desloratadine.Approved
Huperzine AThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Huperzine A.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desloratadine.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Desloratadine.Approved, Vet Approved
HydrocodoneDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Desloratadine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Desloratadine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Desloratadine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desloratadine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Desloratadine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Desloratadine.Approved
IpidacrineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desloratadine.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Desloratadine.Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desloratadine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Desloratadine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Desloratadine.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Desloratadine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Desloratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desloratadine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desloratadine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Desloratadine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MalathionThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Malathion.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desloratadine.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mazaticol.Experimental
MebicarThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Desloratadine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Desloratadine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Desloratadine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Melperone.Approved, Investigational
MemantineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Memantine.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Desloratadine.Investigational
MephentermineMephentermine may decrease the sedative activities of Desloratadine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desloratadine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Desloratadine.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Desloratadine.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desloratadine.Approved
MethotrimeprazineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Desloratadine.Experimental
MethscopolamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methscopolamine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Desloratadine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methylphenobarbital.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Desloratadine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Desloratadine.Approved, Investigational
MetyrosineDesloratadine may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Desloratadine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desloratadine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Desloratadine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Desloratadine is combined with Milnacipran.Approved, Investigational
MinaprineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mirabegron.Approved
MirtazapineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Desloratadine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Morphine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Desloratadine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone.Approved, Withdrawn
NeostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Nicomorphine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Desloratadine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Desloratadine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Desloratadine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Desloratadine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desloratadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Opium.Approved, Illicit
OrphenadrineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Desloratadine is combined with Osanetant.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desloratadine.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxitropium.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxybuprocaine.Approved, Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Desloratadine.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Desloratadine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pancuronium.Approved
ParaldehydeDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParaoxonThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Paraoxon.Experimental
ParoxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Desloratadine.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desloratadine.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
PerazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Desloratadine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desloratadine.Approved
PethidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Desloratadine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Desloratadine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desloratadine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may decrease the sedative activities of Desloratadine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Desloratadine.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Physostigmine.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Desloratadine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipotiazine.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Desloratadine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Desloratadine.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pizotifen.Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Desloratadine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pomalidomide.Approved
Potassium ChlorideDesloratadine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramipexoleDesloratadine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Desloratadine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Desloratadine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Desloratadine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desloratadine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Desloratadine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Desloratadine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Desloratadine is combined with Propanidid.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Desloratadine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Proparacaine.Approved, Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desloratadine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Desloratadine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Desloratadine.Approved
PSD502The risk or severity of adverse effects can be increased when Desloratadine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Desloratadine.Approved
PyridostigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Desloratadine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Desloratadine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Desloratadine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Desloratadine.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ramelteon.Approved, Investigational
RamosetronDesloratadine may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Desloratadine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Desloratadine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Desloratadine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Desloratadine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Desloratadine.Investigational
RivastigmineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Rivastigmine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Romifidine.Vet Approved
RopiniroleDesloratadine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ropivacaine.Approved
RotigotineDesloratadine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Desloratadine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Desloratadine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desloratadine.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Desloratadine.Approved, Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desloratadine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Desloratadine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Solifenacin.Approved
StiripentolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sufentanil.Approved, Investigational
SulpirideDesloratadine may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sultopride.Experimental
SuvorexantDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TacrineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TandospironeThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tasimelteon.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desloratadine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tetrodotoxin.Investigational
ThalidomideDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Desloratadine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Desloratadine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Desloratadine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Desloratadine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desloratadine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tilidine.Experimental
TiotropiumDesloratadine may increase the anticholinergic activities of Tiotropium.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Desloratadine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Desloratadine.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Desloratadine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tramadol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desloratadine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tricaine methanesulfonate.Vet Approved
TrichlorfonThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Desloratadine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desloratadine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Desloratadine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Desloratadine is combined with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desloratadine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Desloratadine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Desloratadine.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Desloratadine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tubocurarine.Approved
TyrothricinThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Tyrothricin.Approved
UmeclidiniumDesloratadine may increase the anticholinergic activities of Umeclidinium.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Desloratadine is combined with Valproic Acid.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vigabatrin.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Desloratadine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Desloratadine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desloratadine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Desloratadine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Desloratadine is combined with Zolazepam.Vet Approved
ZolpidemDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desloratadine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Desloratadine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desloratadine.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Zoltan Toth, "Processes for preparation of polymorphic forms of desloratadine." U.S. Patent US20040242619, issued December 02, 2004.

US20040242619
General References
  1. Mann RD, Pearce GL, Dunn N, Shakir S: Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000 Apr 29;320(7243):1184-6. [PubMed:10784544]
  2. Glass DJ, Harper AS: Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Fam Pract. 2003 Aug 13;4:10. Epub 2003 Aug 13. [PubMed:12917016]
  3. See S: Desloratadine for allergic rhinitis. Am Fam Physician. 2003 Nov 15;68(10):2015-6. [PubMed:14655812]
  4. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052]
  5. Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. doi: 10.1016/j.clinthera.2009.05.017. [PubMed:19539095]
  6. DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83. [PubMed:17902729]
  7. Bachert C, Maurer M: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010;30(2):109-22. doi: 10.2165/11530930-000000000-00000. [PubMed:20067329]
  8. Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. [PubMed:12642846]
External Links
Human Metabolome Database
HMDB0015102
PubChem Compound
124087
PubChem Substance
46507996
ChemSpider
110575
BindingDB
50073179
ChEBI
291342
ChEMBL
CHEMBL1172
Therapeutic Targets Database
DAP000331
PharmGKB
PA164776964
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Desloratadine
ATC Codes
R06AX27 — Desloratadine
AHFS Codes
  • 04:08.00 — Second Generation Antihistamines
FDA label
Download (200 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers4
2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentPost-nasal Drip / Rhinorrhea / Seasonal Allergic Rhinitis (SAR)1
2, 3CompletedTreatmentAllergies1
3CompletedNot AvailableAllergic Rhinitis (AR)2
3CompletedTreatmentAllergic Rhinitis (AR)2
3CompletedTreatmentAllergic Rhinoconjunctivitis1
3CompletedTreatmentAsthma Bronchial / Rhinitis, Allergic, Seasonal1
3CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentAtopics / Chronic Idiopathic Urticaria1
3CompletedTreatmentChronic Urticaria1
3CompletedTreatmentDermal Pruritus / Dermatitis, Eczematous / Skin Inflammation1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)3
3CompletedTreatmentUrticarias2
3Not Yet RecruitingTreatmentCold1
3TerminatedTreatmentCutaneous Hypersensitivity1
3Unknown StatusTreatmentAllergic Rhinitis (AR)1
4CompletedNot AvailableAllergies2
4CompletedNot AvailablePerennial Allergic Rhinitis (PAR) / Seasonal Allergic Rhinitis (SAR)3
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)2
4CompletedDiagnosticAsthma Bronchial1
4CompletedOtherSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentAcquired Cold Urticaria1
4CompletedTreatmentAllergic Airway Disease1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentChronic Idiopathic Urticaria1
4CompletedTreatmentChronic Idiopathic Urticaria / Urticarias1
4CompletedTreatmentConjunctivitis, Seasonal Allergic1
4CompletedTreatmentHypersensitivity1
4CompletedTreatmentRhinitis, Allergic, Seasonal1
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)3
4CompletedTreatmentUrticarias4
4TerminatedTreatmentUrticarias1
Not AvailableCompletedNot AvailableRhinitis1
Not AvailableCompletedNot AvailableRhinitis / Urticarias2
Not AvailableCompletedTreatmentAsthma Bronchial1
Not AvailableSuspendedTreatmentAsthma Bronchial / Rhinitis1

Pharmacoeconomics

Manufacturers
  • Schering corp
  • Doctor reddys laboratories ltd
  • Schering plough corp
  • Orchid healthcare
Packagers
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Cima Laboratories Inc.
  • Lake Erie Medical and Surgical Supply
  • Schering Corp.
  • Schering-Plough Inc.
  • Southwood Pharmaceuticals
Dosage forms
FormRouteStrength
SyrupOral0.5 mg
Tablet, multilayer, extended releaseOral
TabletOral5 mg
SolutionOral.5 mg/mL
Tablet, extended releaseOral
Tablet, film coatedOral5 mg
TabletOral5 mg/1
Tablet, film coatedOral5 mg/1
Tablet, orally disintegratingOral2.5 mg/1
Tablet, orally disintegratingOral5 mg/1
SolutionOral0.5 mg/ml
Tablet, orally disintegratingOral2.5 mg
Tablet, orally disintegratingOral5 mg
Prices
Unit descriptionCostUnit
Clarinex Reditabs 30 5 mg Dispersible Tablet Box150.0USD box
Clarinex Reditabs 30 2.5 mg Dispersible Tablet Box147.14USD box
Clarinex-D 24 Hour 5-240 mg 24 Hour tablet5.0USD tablet
Clarinex-d 24 hour tablet4.8USD tablet
Clarinex 5 mg tablet4.57USD tablet
Clarinex-D 12 Hour 2.5-120 mg 12 Hour tablet3.2USD tablet
Clarinex-d 12 hour tablet3.08USD tablet
Clarinex 0.5 mg/ml Syrup0.48USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878No1993-01-122010-01-12Us
CA2294352No2008-05-062018-07-01Canada
CA2267136No2000-11-282018-02-06Canada
US7405223Yes2000-01-072020-01-07Us
US6100274Yes2000-01-072020-01-07Us
US6514520Yes1998-12-012018-12-01Us
US7618649Yes2001-06-192021-06-19Us
US6709676No2001-02-182021-02-18Us
US8187630No2000-12-192020-12-19Us
US6979463No2002-03-282022-03-28Us
US7820199Yes2002-09-282022-09-28Us
US5607697Yes1995-12-072015-12-07Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00395 mg/mLALOGPS
logP3.48ALOGPS
logP3.97ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)9.73ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.92 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity101.04 m3·mol-1ChemAxon
Polarizability34.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.965
Caco-2 permeable-0.5121
P-glycoprotein substrateSubstrate0.7758
P-glycoprotein inhibitor IInhibitor0.6694
P-glycoprotein inhibitor IINon-inhibitor0.794
Renal organic cation transporterInhibitor0.6979
CYP450 2C9 substrateNon-substrate0.8554
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5634
CYP450 1A2 substrateInhibitor0.7786
CYP450 2C9 inhibitorNon-inhibitor0.738
CYP450 2D6 inhibitorNon-inhibitor0.7377
CYP450 2C19 inhibitorNon-inhibitor0.7837
CYP450 3A4 inhibitorNon-inhibitor0.8332
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.6514
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0370 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7382
hERG inhibition (predictor II)Inhibitor0.8016
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0940000000-d20368a648c20c37e1a0
MS/MS Spectrum - , positiveLC-MS/MSsplash10-08fr-0095000000-2816aba50d0b94d568cf
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0940000000-9a0f5f4d81f4c42c85bb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-08fr-0095000000-5b3f7555b72461661fa1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0bt9-0094000000-536b5a1d05f7479c2b04

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzocycloheptapyridines. These are aromatic compounds containing a benzene ring and a pyridine ring fused to a seven membered carbocycle.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzocycloheptapyridines
Sub Class
Not Available
Direct Parent
Benzocycloheptapyridines
Alternative Parents
Pyridines and derivatives / Piperidines / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
Benzocycloheptapyridine / Aryl chloride / Aryl halide / Piperidine / Pyridine / Benzenoid / Heteroaromatic compound / Secondary amine / Secondary aliphatic amine / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzocycloheptapyridine (CHEBI:291342)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Wu RL, Anthes JC, Kreutner W, Harris AG, West RE Jr: Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. Int Arch Allergy Immunol. 2004 Dec;135(4):313-8. Epub 2004 Nov 24. [PubMed:15564772]
  2. Cieslewicz G, Gondorowicz K, Grzelewska-Rzymowska I, Rozniecki J: [Effect of loratadine, selective antagonist of histamine H1 receptors, on histamine-induced bronchoconstriction]. Pneumonol Alergol Pol. 1995;63(5-6):281-5. [PubMed:7581058]
  3. Letari O, Miozzo A, Folco G, Belloni PA, Sala A, Rovati GE, Nicosia S: Effects of loratadine on cytosolic Ca2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur J Pharmacol. 1994 Feb 15;266(3):219-27. [PubMed:8174605]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052]
  6. DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83. [PubMed:17902729]
  7. Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. [PubMed:12642846]
  8. Dhanya NB, Thasleem Z, Rai R, Srinivas CR: Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol. 2008 Jul-Aug;74(4):361-3. [PubMed:18797058]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [PubMed:11454724]

Drug created on June 13, 2005 07:24 / Updated on June 24, 2018 20:22